Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trialRandomized Controlled Trial Published on 2021-05-012022-10-05 Journal: International Journal of Infectious Diseases [Category] 임상, [키워드] age assigned Asymptomatic baseline Chemoprophylaxis Cluster Combination Complete confidence interval coronavirus disease COVID-19 defined Evidence examined healthy highest Hydroxychloroquine interruption Ivermectin Laboratory men Open-label participant positive positive PCR test povidone-iodine primary analysis Primary outcome Prophylaxis Randomized controlled trial randomized trial Randomly receive reduce reducing regimen risk reduction SARS-CoV-2 SARS-CoV-2 antibody SARS-COV-2 infection seronegative shown Side effect Singapore Spread statistically significant difference Vitamin Vitamin C was performed Zinc [DOI] 10.1016/j.ijid.2021.04.035 PMC 바로가기 [Article Type] Randomized Controlled Trial
Clinical Variants, Characteristics, and Outcomes Among COVID-19 Patients: A Case Series Analysis at a Tertiary Care Hospital in Karachi, PakistanMedical Education Published on 2021-04-292022-10-31 Journal: Cureus [Category] COVID-19, [키워드] acute respiratory distress affecting age Alter alteration ARDS C-reactive protein (CRP Care case sery CBC chest imaging clinical clinical markers comorbid condition comorbid conditions Comorbidity complete blood count complications Computed tomography concerning conducted Coronavirus disease 2019 COVID-19 COVID-19 patient COVID-19 patients COVID-19 severity CRP level death demographic characteristics diabete died discharged disease mortality Disease progression disease severity disease-associated doxycycline dry cough ECG effective estimate expired ferritin Fever Final hematological High-resolution hospital Hospital stay HRCT inflammatory markers Ivermectin Karachi Laboratory lactate dehydrogenase LDH Liver function test majority male medical records Mortality Neutrophil-to-lymphocyte ratio NLR outcome outcomes oxygen saturation Pakistan patchy Patient performed predictor predictors Prognosis proportion public health questionnaire radiographic abnormalities reducing Remdesivir renal reported symptoms Result Science Sepsis Sery severity significantly sodium SPSS Statistical Package steroid Symptoms syndrome Tertiary therapeutic option Tocilizumab Treatment was done were recorded X-ray [DOI] 10.7759/cureus.14761 PMC 바로가기 [Article Type] Medical Education
From informed consent to adherence: factors influencing involvement in mass drug administration with ivermectin for malaria elimination in The Gambia정보에 기반한 동의에서 준수까지: 감비아에서 말라리아 제거를 위한 이버멕틴 대량 약물 투여 참여에 영향을 미치는 요인Research Published on 2021-04-262024-08-08 Journal: Malaria Journal [Category] 말라리아, [키워드] adherence Ivermectin malaria MDA Participation The Gambia [DOI] 10.1186/s12936-021-03732-z PMC 바로가기 [Article Type] Research
Drug Repurposing Approach, Potential Drugs, and Novel Drug Targets for COVID-19 TreatmentCOVID-19 치료를 위한 약물 용도 변경 접근법, 잠재적 약물 및 새로운 약물 목표Review Published on 2021-04-222022-09-10 Journal: Journal of Environmental and Public Health [Category] SARS, 신약개발, 치료제, [키워드] angiotensin Angiotensin-converting enzyme angiotensin-converting enzyme 2 antibodies available data CD147 coronavirus Corticosteroids COVID-19 COVID-19 infection COVID-19 treatment COVID19 Cytokines dipeptidyl peptidase Dipeptidyl peptidase 4 drug Drug discovery Drug repurposing drug target effective enzyme eradication explicit Gene Expression identify include inhibitor inhibitors interferons Ivermectin management medication melatonin membrane fusion MERS-CoV molecular target novel Novel coronavirus nucleic acid other disease other diseases Potential protease inhibitors Protein repositioning repurposing RNA virus RNA-dependent RNA polymerase SARS-CoV structural protein Support target Teicoplanin therapeutic therapeutic agent therapeutic agents therapy treat treating COVID-19 Treatment Vaccines variety Viral virus viruses Wuhan Wuhan, China [DOI] 10.1155/2021/6631721 PMC 바로가기 [Article Type] Review
Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical TrialRandomized Controlled Trial Published on 2021-04-132022-10-05 Journal: JAMA [Category] SARS, 임상, [키워드] adverse event clinical clinical benefit clinically collected conducted Course COVID-19 database determine Effect enrolled follow-up period hazard ratio headache Health Hospitalized IMPROVE IQR Ivermectin ivermectin group laboratory-confirmed log-rank test median age median time Mild multiorgan failure outcome outcomes Patient per day Placebo Potential Potential treatment primary analysis population random Randomized randomized trial receive reported Resolution resolution of symptom resolution of symptoms resolved Serious Adverse Event significantly study participant study period Support Symptom symptomatic Symptoms the placebo group time Treatment Trial with mild disease women [DOI] 10.1001/jama.2021.3071 PMC 바로가기 [Article Type] Randomized Controlled Trial
Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial페루의 초기 COVID-19 환자(SAINT-Peru)에서 비인두 PCR을 무효화하기 위해 이버멕틴 대 위약의 효능을 비교하기 위한 무작위 임상 시험(SAINT-Peru): 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2021-04-092022-09-01 Journal: Trials [Category] MERS, 임상, 진단, [키워드] 1:1 Administered adverse event allergy Amiodarone Anosmia Antiviral attending physician baseline blinded Blinding block childbearing age clarithromycin clinical clinical and laboratory parameters clinical care clinical trial Cobicistat coin conducted control group correlation cough COVID-19 COVID-19 disease COVID-19 patient COVID-19 pneumonia COVID-19 progression criteria Critical current cyclosporine CYP3A4 daily dose death determine determined by diagnosed diagnostic test Diltiazem dissemination dose drug early treatment Efficacy element Eligible patients emergency services enrolled epidemiologist erythromycin evaluate expected Fever follow-up visits generate hospital Hospitalization IgA IgG IgM IIa immune response immunomodulatory in vivo include inclusion criteria Indinavir Infection Informed consent inhibitor Intervention intestinal investigator investigators involved itraconazole Ivermectin ketoconazole laboratory parameter less list lung magnitude medical staff nasopharyngeal nasopharyngeal specimen Nasopharyngeal swab nasopharyngeal swab PCR nasopharyngeal swabs National negative number objective Older outcome oxygen oxygen saturation Parallel Arm participant Patient patients patients with SARS-CoV-2 PCR PCR cycle Peru Pharmacist phase Placebo placebo group placebo-controlled trial Pneumonia positive positive PCR test positive SARS-CoV-2 PCR pregnancy test pregnant women principal investigator progression proportion protocol quinidine randomization list Randomized Randomized controlled trial Randomly Rapid diagnostic test receive recruited reduce Registered Registration Result risk factor Risk factors Ritonavir Sample size SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 PCR SARS-CoV-2 RNA SARS-CoV-2 viral load secondary Secondary objectives Seroconversion Seven severe disease severity spironolactone statistician status study population Study protocol supplementary material Symptom symptomatic Symptomatology Symptoms tacrolimus the patient the placebo group the SARS-CoV-2 threshold Treatment treatment group treatment groups treatment initiation Trial Trial registration two group two groups verapamil Viral Viral load virus Warfarin website with COVID-19 women [DOI] 10.1186/s13063-021-05236-2 PMC 바로가기 [Article Type] Letter
Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients중증 코로나19 환자 치료에 이버멕틴 추가의 유효성 및 안전성 평가Clinical Trial Published on 2021-04-042022-07-29 Journal: BMC Infectious Diseases [Category] 임상, 치료제, [키워드] added affecting Alter average Azithromycin azithromycin- blood lymphocyte count C-reactive protein can be used cause changes in Clinical improvement clinical recovery clinical response control group control groups COVID-19 COVID-19 disease COVID-19 pandemic COVID-19 pneumonia COVID19 pneumonia CRP D-dimer level D-dimer levels decrease drug Effect effective Effectiveness enteral use evaluate evaluated Favipiravir ferritin FiO2 follow-up period gene mutation gene mutations genetic test genetic tests groups Hydroxychloroquine increase in investigated Ivermectin ivermectin metabolism ivermectin treatment laboratory parameter Laboratory parameters lymphocyte material metabolism Mortality mortality rate mortality rates Mutation oxygen oxygen saturation PaO2 partial pressure Partial pressure of oxygen Patient patients performing sequence analysis peripheral capillary phase 3 study Pneumonia prognostic protocol protocols randomization Randomized reduction in reference treatment Result Sanger method SARS CoV-2 SARS-CoV2 Sequence analysis serum serum C-reactive protein severe COVID-19 severe COVID-19 patient Severe COVID-19 pneumonia single-blind solution SpO2 study group supplementary material the study group toxic effect toxic effects Treatment two groups were excluded were given while PMC 바로가기 [Article Type] Clinical Trial
A systematic review of experimental evidence for antiviral effects of ivermectin and an in silico analysis of ivermectin’s possible mode of action against SARS-CoV-2이버멕틴의 항바이러스 효과에 대한 실험적 증거의 체계적인 검토 및 SARS-CoV-2에 대한 이버멕틴의 가능한 작용 방식에 대한 실리코 분석Review Published on 2021-04-012022-09-11 Journal: Fundamental & clinical pharmacology [Category] SARS, 신약개발, 치료제, [키워드] 95% confidence interval Antiviral antiviral agent Antiviral effect applicability applied Circoviridae Clinical efficacy Control Coronaviridae Coronaviridae family determine Developing dose economic loss Efficacy Evidence experimental evidence facilitated Flaviviridae Host in silico analysis in vitro In vitro studies in vitro study in vivo infected cell infected cells Infection infections inhibited Ivermectin mammalian mechanism meta-analyses Meta-analysis mice multiple organs nuclear nuclear location signals. nuclear translocation pharmacokinetic Propagation Replication SARS-CoV-2 SARS-CoV-2 genome selective shown standardized mean difference systematic review therapeutic agents toxic Toxicity Trial unmet need viral infection viral infections Viral proteins viral replication virus while [DOI] 10.1111/fcp.12644 PMC 바로가기 [Article Type] Review
Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico멕시코 틀락스칼라(Tlaxcala)의 외래 코로나19 환자에서 이버멕틴, 아지트로마이신, 몬테루카스트, 아세틸살리실산으로 구성된 다제 요법의 효과Article Published on 2021-04-012022-09-11 Journal: International Journal of Infectious Diseases [Category] SARS, 치료제, [키워드] Acetylsalicylic acid All participant All participants Ambulatory care attenuate Azithromycin Care clinical evaluation COVID-19 COVID-19 case COVID-19 cases death effective Effectiveness Endotheliitis Enrollment greater Hospitalization Hospitalized Ivermectin likelihood lower risk lung Mexico Ministry of Health Montelukast Prevent prevented risk SARS-CoV-2 systemic inflammation therapy thrombosis treated Treatment was performed [DOI] 10.1016/j.ijid.2021.02.014 PMC 바로가기 [Article Type] Article
Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment정량적 단백질체학은 COVID-19 치료에 도움이 되는 이버멕틴의 광범위한 항바이러스 특성을 나타냅니다Article Published on 2021-04-012022-09-11 Journal: Journal of cellular physiology [Category] SARS, 유전자 메커니즘, 치료기술, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 alteration Amino acid amino acids Analysis Antibacterial anticancer Antiviral biological processes Cancer cells Cell Cell culture cells cellular components complex coronavirus COVID-19 COVID-19 treatment cytokine Cytokines cytomegalovirus Diseases EBV Epstein-Barr virus G-protein Gene ontology Gene ontology analysis global public health growth factor HCMV Health HIV HIV1 HLA HPV Human Cytomegalovirus Human immunodeficiency virus human papillomavirus identify immunodeficiency virus IMPROVE in vitro Infection inhibit Interaction Ivermectin labeling molecular functions network analysis offer ovarian cancer papillomavirus pathway Pathways Personalized medicine PPI PPI network Predictive Protein Proteins proteomics Quantitative quantitative proteomics regulated Replication replication of SARS-CoV-2 reported reveal SARS-CoV-2/COVID-19 STABLE stable isotope labeling by amino acids in cell culture statistically significant treated Treatment virus virus infection virus-related pathways. was used [DOI] 10.1002/jcp.30055 PMC 바로가기 [Article Type] Article